BHC
Bausch Health Companies Inc
Healthcare
04/10/2019
Presented
| Date | 04/04/2019 |
| Price | $24.96 |
| Market Cap | $8.76B |
| Ent Value | $30.13B |
| P/E Ratio | N/A |
| Book Value | $7.81 |
| Div Yield | 0% |
| Shares O/S | 351.01M |
| Ave Daily Vol | 4,114,136 |
| Short Int | 3.09% |
Current
| Price | $8.39 |
| Market Cap | $3.08B |
| Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada. |
Publicly traded companies mentioned herein: Allergan PLC (AGN), Bausch Health Companies Inc (BHC), Takeda Pharmaceutical Co Ltd (4502 JP; TAK), Teva Pharmaceutical Industries Ltd (TEVA)
Highlights
Shares of Bausch Health (BHC), formerly Valeant Pharmaceuticals, have performed well over the past 12 months (+66%), but the presenter thinks the risk/reward may still be skewed to the upside. After bottoming-out in the $8 - $9 range in 2017, it looks like the company has found more solid footing. And, while it’s going to take time to delever organically, and for investors to value the heavily levered company in a more favorable way (i.e., on a P/E basis versus EV/EBITDA), there are a number of interesting potential call options that could drive as much as 100% upside for the stock (from the mid-$20s, today).
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.